Biotech SPAC boom continues: Data Byte

At least 22 biotech companies have announced plans to go public via a SPAC this year, according to BioCentury’s BCIQ database, doubling last year’s haul. 

Unlike the special purpose acquisition companies (SPACs) of previous decades, this latest cohort of SPACs is backed by blue chip specialist biotech investors. The financing vehicle emerged last year as an alternative path to the public markets, and it appears it’s here to stay, at least for now...